Department of Pediatric Nephrology and Rheumatology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China.
Lupus. 2023 Apr;32(5):680-687. doi: 10.1177/09612033231164633. Epub 2023 Mar 13.
The aim of this study was to investigate serum levels of soluble B-cell maturation antigen (sBCMA) in childhood-onset systemic lupus erythematous (cSLE) patients with renal involvement, and to elucidate their association with clinical characteristics.
116 cases of cSLE patients with renal involvement (84 females and 32 males; median age 11.6 (10.1, 12.9) years) hospitalized in Department of Pediatric Nephrology and Rheumatology, the First Affiliated Hospital, Sun Yat-sen University and 31 healthy controls (HCs) were enrolled. Serum concentrations of sBCMA were determined using enzyme-linked immunosorbent assay (ELISA). Clinical and laboratory information of cSLE patients were retrospectively analyzed.
Serum sBCMA levels were significantly increased in primary cSLE when compared with treated cSLE patients and HCs, whereas there was no significant difference between treated cSLE patients and HCs. Patients with high disease activity displayed higher serum sBCMA levels compared with those with no or mild to moderate disease activity. Positive correlation was observed between serum sBCMA levels and systemic lupus erythematosus disease activity index-2K (SLEDAI-2K), antinuclear antibody titers, anti-double-stranded DNA titers, erythrocyte sedimentation rate, and immunoglobulin G levels, while sBCMA levels were negatively correlated with blood white blood cell count, hemoglobin, platelet count, complement C3 and C4 levels. Serum sBCMA levels decreased as disease ameliorated after treatments among 11 cases with follow-up examinations.
In cSLE patients with renal involvement, serum sBCMA levels correlated significantly with disease activity, immunological, and hematological parameters, but not with renal parameters. Our results suggest the potential and significance of serum sBCMA as a biomarker in cSLE patients.
本研究旨在探讨伴有肾脏受累的儿童发病系统性红斑狼疮(cSLE)患者血清可溶性 B 细胞成熟抗原(sBCMA)水平,并阐明其与临床特征的关系。
纳入中山大学附属第一医院儿科肾脏风湿科收治的 116 例伴有肾脏受累的 cSLE 患者(女性 84 例,男性 32 例;中位年龄 11.6(10.1,12.9)岁)及 31 名健康对照者(HCs)。采用酶联免疫吸附试验(ELISA)检测血清 sBCMA 浓度。回顾性分析 cSLE 患者的临床和实验室资料。
与治疗后的 cSLE 患者和 HCs 相比,初发 cSLE 患者的血清 sBCMA 水平显著升高,而治疗后的 cSLE 患者与 HCs 之间的 sBCMA 水平无显著差异。疾病活动度高的患者血清 sBCMA 水平高于疾病活动度无或轻中度的患者。血清 sBCMA 水平与系统性红斑狼疮疾病活动指数-2K(SLEDAI-2K)、抗核抗体滴度、抗双链 DNA 滴度、红细胞沉降率和免疫球蛋白 G 水平呈正相关,与白细胞计数、血红蛋白、血小板计数、补体 C3 和 C4 水平呈负相关。在 11 例有随访检查的患者中,治疗后疾病缓解时血清 sBCMA 水平降低。
在伴有肾脏受累的 cSLE 患者中,血清 sBCMA 水平与疾病活动度、免疫和血液学参数显著相关,与肾脏参数无关。我们的结果表明,血清 sBCMA 作为 cSLE 患者的生物标志物具有潜在意义。